TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06593847

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Single-session VR exposure intervention
Description: VR exposure is the only intervention, but the VR intervention is conducted following either positive or negative mood induction.
Study: NCT06599164

Intervention type: OTHER
Intervention: Anthrogenic Muscle Inhibition (AMI) Assessment Protocol
Description: This study involves evaluating Anthrogenic Muscle Inhibition (AMI) of the vastus medialis muscle in futsal players. The intervention includes assessments of muscle strength, AMI using electromyography, ultrasound evaluation, and single-leg vertical jump tests. These evaluations are conducted at different stages throughout the season: pre-season, 4 months in, and at the end of the season. The goal is to compare AMI levels and muscle function between players with ACL injuries and those without.

Intervention type: OTHER
Intervention: Anthrogenic Muscle Inhibition (AMI) Assessment Protocol
Description: This study involves evaluating Anthrogenic Muscle Inhibition (AMI) of the vastus medialis muscle in futsal players. The intervention includes assessments of muscle strength, AMI using electromyography, ultrasound evaluation, and single-leg vertical jump tests. These evaluations are conducted at different stages throughout the season: pre-season, 4 months in, and at the end of the season. The goal is to compare AMI levels and muscle function between players with ACL injuries and those without.
Study: NCT05462951

Intervention type: RADIATION
Intervention: Standard
Description: Radiation then brachytherapy
Study: NCT06171009

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Coping Information
Description: A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Pain Management
Description: A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
Study: NCT06587477

Intervention type: OTHER
Intervention: Hormonal profile
Description: Blood for FSH, LH, testosterone

Intervention type: OTHER
Intervention: Hormonal profile
Description: Blood for FSH, LH, testosterone

Intervention type: OTHER
Intervention: Semen analysis
Description: Semen analysis

Intervention type: OTHER
Intervention: Semen analysis
Description: Semen analysis

Intervention type: OTHER
Intervention: Questionnaire
Description: The European Male Ageing Study (EMAS) questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Description: The European Male Ageing Study (EMAS) questionnaire
Study: NCT06628284

Intervention type: DEVICE
Intervention: Dexcom G7
Description: The study will be conducted as a single-arm trial consisting of participants enrolled in the test group. Each participant will receive a G7 CGM and their blood glucose levels will be continuously transmitted to the Dexcom Clarity system for monitoring and data collection. As a observational study, the test group glucose levels will be monitored after receiving a steroid for pain management. The CGM profile of steroid-induced hyperglycemia in patients will be studied for the following corticosteroids: dexamethasone (10 mg), methylprednisolone (40 mg or 80 mg), triamcinolone (40 mg or 80 mg).
Study: NCT04815876

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal MRI-guided prostate biopsy
Description: Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal MRI-guided prostate biopsy
Description: Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic (prophylaxis)
Description: For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy.
Study: NCT06303115

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Pouch P1312914, 4 mg nicotine
Description: P1312914 pouch product

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Pouch P1312915, 8 mg nicotine
Description: P1312915 pouch product

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Pouch P1013215, 8 mg nicotine
Description: P1013215 pouch product

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Pouch P1013218, 10 mg nicotine
Description: P1013218 pouch product

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Pouch P1012919, 12 mg nicotine
Description: P1012919 pouch product

Intervention type: OTHER
Group type: OTHER
Intervention: Smoking Abstinence
Description: No tobacco/nicotine

Intervention type: OTHER
Group type: OTHER
Intervention: Continued UB cigarette smoking
Description: Usual Brand Cigarette
Study: NCT06705452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional 4D Flow MRI or additional 4D Flow sequence
Description: Additional 4D Flow MRI or additional 4D Flow sequence
Study: NCT06704685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide
Description: Subjects who were initially diagnosed with STEMI and scheduled for PCI were randomly assigned to one of two groups in a 1:1 ratio: a butylphthalide group and a placebo group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Butylphthalide placebo
Description: Butylphthalide placebo
Study: NCT05232682

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seed DS-01 Daily Synbiotic
Description: Daily administration of Seed DS-01 Daily Synbiotic (dietary supplement)
Study: NCT05444348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance consultation concerning your life and treatment (ACT )
Description: The ACT intervention consists of: an 8 h training day for clinicians including clinical materials such as a conversation aid and conversations guide. 6o minutes ACT-intervention sessions in daily clinic. the patients and caregivers will receive preparatory material prior for the ACT-intervention sessions, and a 30 min follow-up telephone call from the nurse within one week after the ACT-session. Clinicians will receive five sessions of followup supervision within the 24 months of intervention. The 60 min ACT-intervention session is an interdisciplinary conversation with nurse, physician, patient, and caregiver discussing issues of importance of patient and caregiver. The issues are based on the preparatory material focusing on information level and prognosis, patient's and caregiver's values, hopes, fears and worries regarding the future care with progressive disease.
Study: NCT06482944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Foods for Families
Description: This diet intervention will encourage the consumption of a whole foods dietary patterns such as a wide variety of fruits, vegetables, proteins, seafood, dairy and whole grains. During the partial feeding period (weeks 3-8), families will be asked to continue the whole foods diet with support that includes: 1) 3 weekly dinners of the families' choosing (described above), 2) rotating menus (\~3 weeks' worth) that will allow for customization (e.g., protein, vegetable, grain swaps) to support cultural/dietary preferences, and 3) dietetic support to help with customization and diet maintenance. Participants will be instructed by the registered dietitian nutritionist (RDN) on how to adhere to the diet intervention and will be provided menus and recipes. For the enrolled families in the study, the goal is to maintain complete diet adherence during the twelve-week intervention.
Study: NCT04794855

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory tests
Description: routine laboratory tests and biomarkers tests
Study: NCT05413759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care in multiprofessional collaboration
Description: In addition to usual practices: medication reconciliation and pharmaceutical motivational interviews with patients (discharge, 2 \& 6 months).~Objective of medication reconciliation (admission): to detect and resolve unintended medication discrepancies between home medication list and treatment and hospital admission medication orders. Objective of medication reconciliation (discharge): to obtain an exact list of medication, to explain the medication modifications during hospitalization.~Objective of the Disease-Modifying Antirheumatic Drugs information interview (discharge): to provide information and to answer questions on the management of treatment, to deal with practical situations to assess patients' self-management skills.~Objective of interviews (2 \& 6 months): to evaluate medications and their daily management, benefits and problems that patient may encounter, to assess the patient's ability to manage the treatment.
Study: NCT05978193

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LDRT+CFRT
Description: LDRT: Primary tumor and all visible metastatic lesions, DT: 2Gy/2fx, d1-2, Q3W × 4 cycles~; CFRT: Primary tumor, DT:40-50Gy/20-25fx, starting from the 5th immunotherapy cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: PD-1 inhibitor 200mg, Q3W, until disease progression or unacceptable toxicity or treatment reaches 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy
Description: PD-1 inhibitor 200mg, Q3W, until disease progression or unacceptable toxicity or treatment reaches 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Paclitaxel+ Cisplatin, Q3W × 4cycles or Paclitaxel+ Carboplatin, Q3W × 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Paclitaxel+ Cisplatin, Q3W × 4cycles or Paclitaxel+ Carboplatin, Q3W × 4 cycles
Study: NCT06290336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-operative exercise therapy and education
Description: Pre-operative supervised exercise therapy consisting of individualized strength, mobility and balance exercises and continuous education through individual discussions of expectations of post-operative recovery, pain and swelling, course of rehabilitation, long term function and activity level etc. Twice a week, approximately one hour/session.

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized pre-operative information session
Description: As part of the standard care procedure, patients in the intervention and control group will participate in a standardized pre-operative information session approximately 2 weeks before surgery. General information regarding preparations before surgery (e.g. preparing the home environment), events during the hospital stay and the rehabilitation process after discharge will be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized pre-operative information session
Description: As part of the standard care procedure, patients in the intervention and control group will participate in a standardized pre-operative information session approximately 2 weeks before surgery. General information regarding preparations before surgery (e.g. preparing the home environment), events during the hospital stay and the rehabilitation process after discharge will be provided.
Study: NCT05356377

Intervention type: DRUG
Intervention: Pegvaliase-Pqpz
Description: Participants will have been prescribed pegvaliase-pqpz (Palynziq) by their primary metabolic care providers as part of their standard care. \[Note that prescription and standard care are independent of the present study.\]
Study: NCT05813106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Intravenous dexmedetomidine 0.2 mcg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline
Study: NCT05641337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec and Insulin Aspart
Description: The hypoglycemic scheme of the experimental group was that the initial dose of Insulin Degludec and Insulin Aspart was 0.3U/kg multiplied by the patient's weight, plus 5 mg of linagliptin and 0.5 g of metformin three times a day. The control group was treated with traditional four needle insulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec and Insulin Aspart
Description: The hypoglycemic scheme of the experimental group was that the initial dose of Insulin Degludec and Insulin Aspart was 0.3U/kg multiplied by the patient's weight, plus 5 mg of linagliptin and 0.5 g of metformin three times a day. The control group was treated with traditional four needle insulin.
Study: NCT06145321

Intervention type: DEVICE
Group type: OTHER
Intervention: G-CSF administration (bolus injection versus intravenous infusion)
Description: Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-CSF administration (bolus injection versus intravenous infusion)
Description: Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)

Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF administration (bolus injection versus intravenous infusion)
Description: Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF administration (bolus injection versus intravenous infusion)
Description: Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)
Study: NCT06462937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise with supervision
Description: Remote exercise will be administered with digital supervision. The Exercise group will receive a personalised program with individual adaptations aiming to perform 3 exercise sessions per week including HIIT, strength exercise and moderate intensive aerobic exercise. Participants will consult their rheumatologist parallel to the SPARK trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise with supervision
Description: Remote exercise will be administered with digital supervision. The Exercise group will receive a personalised program with individual adaptations aiming to perform 3 exercise sessions per week including HIIT, strength exercise and moderate intensive aerobic exercise. Participants will consult their rheumatologist parallel to the SPARK trial.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise without supervision
Description: Remote exercise will be administered without digital supervision. Participants will receive a standard exercise program fulfilling the exercise protocol requirements, the exercise program will progress. But there will be no direct contact between the participant and the coach. Participants will consult their rheumatologist parallel to the SPARK trial.
Study: NCT05957835

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BR-HIGH
Description: 4 x nitrate-rich beetroot juice shots (26 mmol of nitrate)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BR-MOD
Description: 2 x nitrate-rich beetroot juice shots + 2 x nitrate-depleted beetroot juice shot (12 mmol of nitrate)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BR-LOW
Description: 1 x nitrate-rich beetroot juice shot + 3 x nitrate-depleted beetroot juice shots (6 mmol of nitrate)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PL
Description: 4 x nitrate-depleted beetroot juice shots (0 mmol of nitrate)
Study: NCT04985279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Position and Angle Marking System
Description: Position and Angular Marking System (PAMS) attaches on to the ultrasound probe. When the desired insertion site is identified by ultrasound, the doctor gently presses PAMS into the patient's back to create skin indentations demarcating the needle insertion point. These indentations are not affected by skin sterilisation, and may improve accuracy and reduce the time taken to perform the epidural procedure. Next, the angle between the ultrasound probe and the patient's back can be measured using PAMS, and this angle can be maintained using a needle guide during the epidural procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard clinical practice
Description: When the desired insertion site is identified by ultrasound, the doctor demarcate the needle insertion point using marker pens.
Study: NCT06210568

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06292260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth app
Description: The eSkinHealth app is a tablet application that can be used as a portable patient chart for dermatological conditions in areas with poor internet connectivity, and for teledermatology when in need.
Study: NCT04879589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: ATRS-2002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: ATRS-2002
Study: NCT06182254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group: OPTIMISTIC follow-up
Description: follow-up by nurses specialized in collecting the patient's point of view concerning his or her state of health, in addition to the usual conventional follow-up according to routine care directive interviews carried out preoperatively and at Days 1, 3, 14 and 28 postoperatively (modified QoR-15f score, PROMS...)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group: Usual conventional follow-up
Description: usual conventional follow-up according to routine care (modified QoR-15f score will be administered to all patients at visit 0 and Day 35).
Study: NCT04953494

Intervention type: DIAGNOSTIC_TEST
Intervention: Patient information collection, exon sequencing and follow-up.
Description: Clinical baseline data, disease characteristics, auxiliary examination results, EMG examination results, drug use and other information were collected. 4-6ml peripheral blood was collected for exon sequencing. The patients were followed up every three months by a specialist in the form of outpatient or telephone.
Study: NCT05742542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Two weeks of high intensity interval training with high or low time spent near VO2max.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Two weeks of high intensity interval training with high or low time spent near VO2max.
Study: NCT04009408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory muscle strength therapy (EMST150, Aspire LLC)
Description: Active therapy calibrated to the participant's maximum expiratory pressure

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Expiratory muscle strength therapy (EMST150, Aspire LLC)
Description: Active therapy calibrated to the participant's maximum expiratory pressure
Study: NCT04345796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol+Empagliflozin
Description: Group A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Group B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Group C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group D
Study: NCT06401486

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscope
Description: For patients assigned to the videolaryngoscope Group, the operator will use a video laryngoscope on the first laryngoscopy attempt.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: For patients assigned to the laryngoscope Group, the operator will use a Macintosh laryngoscope on the first laryngoscopy attempt.
Study: NCT05097079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYOBLOC Low Dose
Description: Subjects assigned to the MYOBLOC Low Dose treatment group will be administered MYOBLOC (60 units/kg; maximum 1800 units) as a single treatment via intraglandular injection (5.0 units/kit per submandibular gland \[maximum 150 units\] and 25.0 units/kg per parotid gland \[maximum 750 units\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYOBLOC High Dose
Description: Subjects assigned to the MYOBLOC High Dose treatment group will be administered MYOBLOC (100 units/kg; maximum 3000 units) as a single treatment via intraglandular injection (25.0 units/kit per submandibular gland \[maximum 300 units\] and 40.0 units/kg per parotid gland \[maximum 1200 units\])

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects assigned to the Placebo treatment group will be administered volume-matched placebo (1:1)
Study: NCT06212362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-by-step
Description: The Step-by-Step follows a stepped care approach, were all children (and caregivers) complete the first step (a brief group intervention followed by an individual session). Those with more needs are offered to continue to step 2 where individual CBT is given.~Step 1 Session 1-4: Group sessions including psychoeducation, parenting skills and mapping stress and vulnerability factors, exposure and coping skills (90 minutes) Session 5: Individual session - If ending after step 1 a maintenance plan is completed. If continuing to step 2 continued exposure and selection of optional focus areas such as emotion regulation, social skills, stress- and vulnerability factors, child worry or parental worry. (45 minutes)~Step 2 Session 6-8: Individual sessions - Exposure and selected focus areas. (45 minutes)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cool Kids
Description: The Cool Kids Program is an Australian manualized group CBT treatment of child anxiety, which has been broadly implemented in Sweden. Several studies have found evidence of its efficacy.~Session 1-10: Group sessions including psychoeducation, cognitive restructuring (gather evidence to reevaluate anxiety related thoughts), parent skills, exposure, social skills, coping skills (cognitive and behavioral strategies to handle anxiety reactions, learning problem-solving skills). (90-120 minutes)
Study: NCT05358665

Intervention type: OTHER
Intervention: mask use
Description: long term mask use

Intervention type: OTHER
Intervention: mask use
Description: long term mask use

Intervention type: OTHER
Intervention: mask use
Description: long term mask use